EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DIS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually. The lecanemab data and additional research findings from Eis

Related Keywords

Tabeta , Mie , Japan , China , United Kingdom , Canada , Great Britain , Robert Perneczky , Sysmex Eisai , Jeffrey Cummings , Miia Kivipelto , Lynn Kramer , Bioarctic Eisai , Ministry Of Health , Alzheimer Clinical Trial Consortium , National Institutes Of Health , Asset In Development , Washington University School Of Medicine , Critical Path For Alzheimer Disease Consortium , National Institute On , Ad Cooperative Study , Biomarkers In Predicting Amyloid Positivity Community , Drug Administration , Eisai Inc , Clinical Research At Eisai Inc , Alzheimer Network Trials Unit , Shimadzu Oita University Eisai , Deputy Chief Clinical Officer , Senior Vice President , Clinical Research , Chief Clinical Officer , Key Compounds , Central European Time , Targeting Therapies , Neuropsychiatric Consequences , Poster Number , Performance Evaluation Of Plasma , Critical Path , Clinical Dementia Rating Sum , Daily Living Scale , Mild Cognitive Impairment , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Binding Profiles , Different Forms , Amyloid Beta Might Explain Efficacy , Side Effects , Clinical Trials , Early Alzheimer , New England Journal , Alzheimer 39s Disease , D , Presentation , Meaningful Benefits , Disai ,